<DOC>
	<DOCNO>NCT02870985</DOCNO>
	<brief_summary>The clinical investigation non-inferiority , multicenter , blind evaluation , randomize , parallel control clinical study enrol 440 subject . All subject randomize 1:1 receive BIOTRONIK Orsiro SES Abbott Xience Prime™ EES , order evaluate efficacy safety SES drug elute stent treatment coronary artery disease .</brief_summary>
	<brief_title>BIOTRONIK Orsiro Pre-Marketing Registration</brief_title>
	<detailed_description>Clinical call follow visit take place 1 , 6 , 12 , 24 , 36 , 48 60 month post procedure . At 9 month ( + 30 day ) subject undergo standard quantitative coronary angiography ( QCA ) follow assess in-stent LLL main efficacious evaluation . Use major adverse cardiac event ( death , myocardial infarction stent thrombosis ) within one year post procedure main safety indicator evaluate investigational product 's safety . The clinical angiographic data sorting , calculation statistical analysis conduct independent data management center angiographic core laboratory .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<criteria>Inclusion CriteriaClinical 1 . Subject understand investigation 's goal provide write informed consent , willing comply study 's followup requirement . 2 . Subject ≥ 18 year ≤ 75 year old , male female without pregnant . 3 . Subject acceptable candidate PCI . 4 . Subject clinical evidence asymptomatic ischemia , stable unstable angina pectoris old myocardial infarction . 5 . Subject contraindication dual antiplatelet therapy treatment . Inclusion CriteriaAngiographic 1 . Target lesion must major coronary artery branch ( target vessel ) . 2 . Target lesion must angiographic evidence ≥ 70 % &lt; 100 % stenosis ( operator 's visual estimate ) . 3 . Subject two target lesion ( two target lesion one target vessel , target vessel , one target lesion ) . 4 . Target lesion suitable drugeluting stent PCI treatment . 5 . Target lesion must ≤ 36 mm length operator 's visual estimate , completely cover one stent . 6 . Target vessel must reference vessel diameter 2.254.0 mm operator 's visual estimate . 7 . Target vessel must Thrombolysis In Myocardial Infarction ( TIMI ) flow ≥ 2 . Exclusion CriteriaClinical 1 . Subject pregnant and/or breastfeed intend become pregnant duration study . 2 . Subject clinical symptom and/or ECG change consistent acute ST elevation MI ( STEMI ) within 7 day prior index procedure , include hemodynamically unstable nonSTEMI ( NSTEMI ) subject . 3 . Subject hemodynamically unstable . 4 . Subject unacceptable candidate CABG . 5 . Subject know allergy contrast medium adequately premedicated , know allergy thienopyridine , aspirin , heparin bivalirudin , L605 cobaltchromium ( CoCr ) alloy one major element ( cobalt , chromium , tungsten nickel ) , acrylic , fluoropolymers , silicon carbide , PLLA , sirolimus everolimus . 6 . Previous revascularization target nontarget vessel 9 month prior index procedure . 7 . Planned surgery within 6 month index procedure . 8 . Planned stag treatment index procedure within 30 day index procedure . 9 . History stroke transient ischemic attack ( TIA ) within 12 month prior index procedure . 10 . Subjects active bleeding disorder , active coagulopathy , reason , ineligible DAPT . 11 . Subject refuse blood transfusion . 12 . Subject document severe cardiac failure ( III level NYHA ) leave ventricular ejection fraction ( LVEF ) ≤ 40 % evaluated echocardiogram , leave ventricular angiography , radionuclide ventriculography noninvasive imaging method within 90 day prior index procedure . 13 . Subject dialysisdependent . 14 . Subject impaired renal function ( i.e. , creatinine &gt; 2.0 mg/dL 175 μmol/L determine ) within 7 day prior index procedure . 15 . Subject leukopenia ( i.e . WBC &lt; 3.5*10*9/L ) , thrombocytopenia ( plt &lt; 100*10*9/L ) thrombocytosis ( PLT &gt; 350*10*9/L ) . 16 . Subject receive chronic anticoagulation ( e.g . coumadin , dabigatran , apixaban , rivaroxaban agent ) . 17 . Subject receive oral intravenous immunosuppressive therapy ( inhaled steroid exclude ) , know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus ; diabetes mellitus exclude ) . 18 . Subject life expectancy &lt; 3 year . 19 . In investigator 's opinion , subject able comply followup requirement . 20 . Subject participate another ( medical device drug ) clinical study . Subjects may concurrently enrol postmarket study , long postmarket study device , drug protocol interfere investigational treatment protocol study . Exclusion CriteriaAngiographic 1 . Target lesion locate within saphenous vein graft arterial graft . 2 . Target lesion follow characteristic : 1 . Lesion location within leave main coronary artery , within 3 mm origin leave anterior descending ( LAD ) leave circumflex ( LCX ) . 2 . Involves side branch &gt; 2.5 mm diameter . Note : Lesions within 3 mm origin right coronary artery may treat . 3 . Target lesion totally occlude ( 100 % stenosis ) . 4 . Target vessel angiographic evidence thrombus . 5 . Target vessel/lesion excessively tortuous/angulated severely calcify , prevent complete inflation angioplasty balloon . 6 . Target vessel treat brachytherapy time prior index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>